Pure red cell aplasia in a patient treated with triple therapy for hepatitis C

• Autores: Marta Hernández Segurado, E. M. Martín Gonzalo, Macarena Bonilla Porras, M. A. Arias Moya, Francisco Javier Bécares Martínez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 16, Nº. 4, 2014, págs. 289-292
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • New protease inhibitors boceprevir and telaprevir for the treatment of hepatitis C virus genotype 1 are expected to obtain higher efficacy than classical therapy, but these drugs are associated with certain undesirable adverse effects. We described a case of pure red cell aplasia in a patient treated with ribavirin, pegylated inter-feron-a and telaprevir. This unexpected serious side effect, not registered in the telaprevir product information, was detected by the pharmacist responsible of pharmaceutical care due to the scheduled visits to the Outpatient Pharmacy Service to pick up the medication. Thus, considering the new experience obtained in clinical practice with the newly marketed protease inhibitors, it would be necessary the development of a strict and detailed protocol to detect and manage severe anemia. Furthermore, it is important to have the full involvement of the pharmacist in order to achieve maximum efficiency of this type of treatments and for detecting avoidable severe adverse reactions